品牌现货直购
供应商:我要出现这里







查看所有供应商和价格请点击:

137281-23-3生产厂家

137281-23-3价格

137281-23-3

137281-23-3结构式
137281-23-3结构式
  • 常用中文名:培美曲塞二钠盐
  • 常用英文名:Pemetrexed disodium
  • CAS号:137281-23-3
  • 分子式:C20H21N5O6
  • 分子量:427.411
  • 相关类别: 信号通路 自噬 自噬
  • 发布时间:2018-04-17 08:00:00
  • 更新时间:2024-01-02 00:29:39
  • Pemetrexed 是一种叶酸拮抗剂 (antifolate)。抑制胸苷酸合成酶 (TS),二氢叶酸还原酶 (DHFR) 和甘氨酰胺核苷酸甲酰转移酶 (GARFT),Ki 分别为 1.3 nM,7.2 nM 和 65 nM。

化源商城直购

中文名 培美曲塞
英文名 pemetrexed
中文别名 N-(4-[2-(2-氨基-4,7-二氢-4-氧-1H-吡咯[2,3-d]嘧啶-5-基)乙基]苯甲酰)-L-谷氨酸
培美曲赛酸
N-[4-[2-(2-胺基-4,7-二氢-4-氧-1H吡咯[2,3-D]嘧啶-5基)乙基]苯甲酰]-L-谷氨酸
培美曲塞二钠盐
培美曲塞酸
英文别名 L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-
n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]l-glutamic acid
Pemetrexed
L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-
Alimta
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
LYA
MFCD00902635
N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid
Pemetrexed acid
N-{4-[2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid
描述 Pemetrexed 是一种叶酸拮抗剂 (antifolate)。抑制胸苷酸合成酶 (TS),二氢叶酸还原酶 (DHFR) 和甘氨酰胺核苷酸甲酰转移酶 (GARFT),Ki 分别为 1.3 nM,7.2 nM 和 65 nM。
相关类别
靶点

Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)[1]

体外研究 培美曲塞(LY231514)二钠是一种新型经典抗叶酸剂,其抗肿瘤活性可能是由于其多聚谷氨酸化代谢物同时和多重抑制几种关键的叶酸需要酶。培美曲塞(LY231514)是已知用于FPGS的最佳底物之一(Km =1.6μM和Vmax/Km = 621)。多糖化和LY231514的多谷氨酸化代谢物可能在确定该新药的选择性和抗肿瘤活性方面发挥重要作用。尽管LY23154仅适度抑制TS(Ki = 340nM,重组小鼠),但LY23154的戊谷氨酸的效力是100倍(Ki = 3.4nM),使得LY231514成为最有效的基于叶酸的TS抑制剂之一[1]。
体内研究 用PC61加培美曲塞治疗的小鼠组在统计学上显示出比其他组更长的存活期。在生存分析中,与单用PC61,大鼠IgG加培美曲塞治疗或未治疗的患者相比,用PC61加培美曲塞治疗的小鼠组观察到明显更好的生存[2]。
激酶实验 通过在A298监测由10-甲酰基 - [6R,S] -5,6,7,8-四氢叶酸的[6S] -5,6,7,8-四氢叶酸的形成,在室温下进行AICARFT抑制试验。所有溶液在使用前用N 2气体吹扫。反应溶液含有33mM Tris-Cl,pH 7.4,25mM KCl,5mM 2-巯基乙醇,0.05mM AICA核糖核苷酸和16nM(2毫单位/ mL)AICARFT。使用10-甲酰基 - [6R,S] -5,6,7,8-四氢叶酸盐浓度0.037,0.074和0.145mM(分别为其Km值的0.61,1.23和2.45倍)。测试LY231514作为0.08-0.8mM(四种浓度)的抑制剂。当LY231514的三 - 和五谷氨酸盐用作抑制剂时,浓度为0.0005-0.009mM(八种浓度)。通过添加酶引发酶测定。使用ENZFITTER程序分析数据以进行竞争性抑制。
细胞实验 产生剂量 - 反应曲线以确定50%生长抑制所需的浓度(IC 50)。培美曲塞最初以4mg / mL的浓度溶解于DMSO中,并进一步用细胞培养基稀释至所需浓度。将完全培养基中的CCRF-CEM白血病细胞加入到24孔Cluster平板中,终浓度为4.8×10 4细胞/孔,总体积为2mL。将各种浓度的测试化合物加入到两个孔中,使得DMSO的最终体积为0.5%。将板在37℃,5%CO 2的空气气氛中温育72小时。在孵育结束时,在ZBI Coulter计数器上测定细胞数。对照孔通常在孵育结束时含有4×105至6×10 5个细胞。对于一些研究,在300μMAICA,5μM胸苷,100μM次黄嘌呤或5μM嘧啶加100μM次黄嘌呤的组合存在下测定每种化合物的IC50 [1]。
动物实验 小鼠[2]使用6-8周龄的雌性CBA小鼠和雌性NOD / SCID小鼠(NOD.CB17-Prkdcscid)。从第4-8天(连续5天)腹膜内给予预甲状腺素(100mg / kg)至荷瘤小鼠,以探索当与抗CD25Ab或IgG对照组合时的协同效应。在当前研究中用于培美曲塞的剂量和时间表是基于先前在小鼠中的研究确定的。
参考文献

[1]. Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.

[2]. Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66.

密度 1.6±0.1 g/cm3
分子式 C20H21N5O6
分子量 427.411
精确质量 427.149170
PSA 191.26000
LogP -0.03
外观性状 固体;White to Blue powder to crystal
折射率 1.724
储存条件 0-10°C;避免加热
水溶解性 微溶:甲醇
更多

1.性状:结晶。

2.熔点(ºC):>250

Material Safety Data Sheet

Section1. Identification of the substance
Product Name: Pemetrexed
Synonyms:(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic
acid

Section2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section3. Composition/information on ingredients.
Ingredient name:Pemetrexed
137281-23-3
CAS number:

Section4. First aid measures
Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Inhalation:
Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution:Wear approved mask/respirator
Hand precaution:Wear suitable gloves/gauntlets
Skin protection:Wear suitable protective clothing
Eye protection:Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section7. Handling and storage
Handling:This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage:Store in closed vessels, refrigerated.

Section8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section9. Physical and chemical properties
Appearance:Not specified
No data
Boiling point:
Melting point:No data
Flash point:No data
Density:No data
Molecular formula:C20H21N5O6
Molecular weight:427.4

Section10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section11. Toxicological information
No data.

Section12. Ecological information
No data.

Section13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section14. Transportation information
Non-harzardous for air and ground transportation.

Section15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A
危害码 (欧洲) Xi
WGK德国 3
海关编码 2933990090

~74%

137281-23-3结构式

137281-23-3

文献:Busolli, Jonathan; Diulgheroff, Nicola; Nemethne Racz, Csilla; Pirkes, Moran; Pontiroli, Alessandro; Villa, Marco; Aronhime, Judith Patent: US2008/45711 A1, 2008 ; Location in patent: Page/Page column 11 ;
上游产品  1

下游产品  0

1. 3-苯甲酰基丙酸的制备

在反应瓶中加入丁二酸酐34.00g(0.34mol) 、苯220ml, 冰浴冷却下搅拌加入无水AlCl3100g(0.75mol), 将混合物继续搅拌一段时间后,搅拌回流1.5h.冷至室温,浓缩,得褐色黏稠状物,加入碎冰及200ml17%稀盐酸,搅匀后静置析出固体,过滤,得淡黄色固体.将其用10%NaOH溶液150ml溶解,过滤后滤液用活性炭脱色,过滤,用稀盐酸酸化,有白色沉淀析出,过滤,滤饼真空干燥,得白色固体3-苯甲酰基丙酸56.2g,收率92%.mp115.4~117.3 ºC.(文献[15]道mp114~115 ºC)

2. 4-苯基丁酸的制备

在反应瓶中加入3-苯甲酰基丙酸23.06g(0.13mol) 、KOH30.10(0.54mol) 、80%水合肼20ml和一缩二乙二醇150ml,搅拌加热至110 ºC,回流1.5h,反应生成水通过分水器从系统除去,升温除水至198 ºC,继续保温搅拌1h.冷至室温,加冰水稀释,再加17%稀盐酸250ml,析出白色固体,过滤得白色固体,纯化方法同上,最后得4-苯基丁酸18.86g, 收率88.4%.mp48.7~50.3 ºC. (文献[17] 报道mp47~51 ºC)

3. 4-苯基丁酸乙酯的制备

在反应瓶中加入4-苯基丁酸19.76g(0.12mol)、对甲苯磺酸4.19g(0.02mol)和乙醇250ml,搅拌回流6h.冷至室温,浓缩,剩余物加乙酸乙酯溶解,过滤除去不溶物,滤液用无水硫酸镁干燥,过滤#滤液浓缩#剩余物经硅胶柱色谱[洗脱剂:乙酸乙酯/石油醚(体积比1:20)]纯化,得无色透明液体4-苯基丁酸乙酯22.60g,收率97.7%.

4. 4-(4-乙氧基-4-氧正丁基)苯甲酸乙酯的制备

在反应瓶中(装置干燥管,并干燥好)加入干燥精制的CH2Cl2 60ml和AlCl3(无水)10.39g(77.92mmol),在N2保护和搅拌下,通过注射器慢慢注入草酰氯[(COCl)2]18ml(211.01mmol),搅拌10min,用恒压漏斗滴加4-苯基丁酸乙酯13.64g(71.0mmol)的CH2Cl2(30ml)溶液,滴加温度控制在18~20 ºC,滴加时间约1h.加毕,减压蒸出过量的(COCl)2和部分CH2Cl2.剩余物缓慢加入碎冰50g和17%稀盐酸20ml,充分振摇后静置分层,分出有机层,水层用CH2Cl2 (15ml×2)提取,合并有机层,加入10%NaOH50ml,室温搅拌过夜,分离水层,用稀盐酸酸化,析出固体,过滤,真空干燥得黄色固体9.40g, 将所得固体按上述酯化方法用乙醇和催化量的TsOH酯化,酯化产物经硅胶柱色谱[洗脱剂:乙酸乙酯/石油醚(体积比1:5)]纯化,得无色透明液体4-(4-乙氧基-4-氧正丁基)苯甲酸乙酯8.57g,收率45.7%.

5. 4-(4-羟基正丁基)苯甲酸乙酯的制备

在干燥反应瓶中加入4-(4-乙氧基-4-氧正丁基)苯甲酸乙酯6.74g(25.50mmol)、KBH411.00g(203.93mmol) 、无水LiBr18.08g(208.20mmol)和150ml无水精制的THF,在N2保护下和30 ºC下搅拌悬浮3天.缓慢滴加1mol/LKHSO4溶液终止反应,减压蒸出大部分THF,过滤,滤液用乙醚(100ml×2)提取,提取液用无水MgSO4干燥,过滤,滤液浓缩,剩余物经硅胶柱色谱[洗脱剂:乙酸乙酯/石油醚(体积比1:2)]纯化,得无色透明液体4-(4-羟基正丁基)苯甲酸乙酯3.08g, 收率53.5%.

6. 4-(4-氧正丁基)苯甲酸乙酯的制备

在反应瓶中加入4-(4-羟基正丁基)苯甲酸乙酯0.78g(3.51mmol)、氯铬酸吡啶盐(PCC)1.51g(7.00mmol)和CH2Cl2 30ml,室温搅拌2h.将反应液预先过一般装有硫酸镁的硅胶柱,将所得粗品浓缩,浓缩液经硅胶柱色谱[洗脱剂:乙酸乙酯/石油醚(体积比1:3.5)]纯化,得4-(4-氧正丁基)苯甲酸乙酯0.64g, 收率86.8%.

7. (RS)-4-(3-溴-4-氧正丁基)苯甲酸乙酯的制备

在反应瓶中加入4-(4-氧正丁基)苯甲酸乙酯2.01g(9.13mmol)、精制干燥的CH2Cl2 40ml,和5,5-二溴巴比妥酸(DBBA).N2保护下,室温搅拌,加入含30%HBr的乙酸溶液250μl,TLC跟踪确认反应终点,反应毕,过滤除去生成的巴比妥酸,滤液依次用1mol/LNa2S2O3溶液50ml、饱和食盐水洗涤,无水硫酸镁干燥,过滤,滤液浓缩,剩余物经硅胶柱色谱[洗脱剂:乙酸乙酯/石油醚(体积比1:3.5)]纯化,得(RS)-4-(3-溴-4-氧正丁基)苯甲酸乙酯1.77g,收率64.8%.

8. 8. 4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸乙酯的制备

在反应瓶中加入(RS)-4-(3-溴-4-氧正丁基)苯甲酸乙酯0.87g(2.91mmol)、2,4-二氨基-6-羟基嘧啶0.37g(2.93mmol)、乙酸钠0.48g(5.85mmol)、乙腈10ml和去离子水10ml, 将悬浮液于40 ºC搅拌反应约3h. 冷至室温,过滤,所得固体真空干燥,经硅胶柱色谱[洗脱剂:甲醇/氯仿(体积比1:8)]纯化,得8. 4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸乙酯0.82g,收率86.3%.mp>260 ºC.

9. 4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸的制备

在反应瓶中加入10%NaOH溶液和8. 4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸乙酯0.51g(1.56mmol),搅拌回流1.5h.冷至室温,加乙醇30ml稀释,加入稀盐酸酸化至pH4.4,过滤,所得固体真空干燥,经硅胶柱色谱[洗脱剂:30%氨水/乙醇(体积比1:80)]纯化,得4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸0.42g,收率90.1%. mp>260 ºC.[文献[12]报道mp>250 ºC]

10. N-{4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酰基}-L-谷氨酸二乙酯的制备

在反应瓶中加入4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸0.3g(1.0mmol)、L-谷氨

酸二乙酯盐酸盐0.30g(1.18mmol)、三乙胺0.04g(3.95mmol)和干燥精制过的DMF15ml,在N2保护下,搅拌一段时间后,加入95%的氰基磷酸二乙酯(DEPC)240μl,室温下继续搅拌,反应过夜.反应结束后将反应液浓缩,剩余物经硅胶柱色谱[洗脱剂:甲醇/氯仿(体积比1:8)]纯化,得N-{4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酰基}-L-谷氨酸二乙酯0.39g,收率79.9%.mp168.4~170.2 ºC[文献[12]报道mp169~170 ºC]

11. N-{4-[2-(2-氨基-4,7-二氢-4-氧-1H-吡咯并[2,3-d] 嘧啶-5-基)乙基]苯甲酰基}-L-谷氨酸(哌美曲塞)的合成

在反应瓶中加入N-{4-[2-(2-氨基-4,7-二氢-4-氧-3H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酰基}-L-谷氨酸二乙酯0.24g(0.50mmol)和THF9ml,搅拌悬浮,再加入1mol/LNaOH水溶液3ml,于室温搅拌反应约2h.减压蒸出THF, 剩余物用稀盐酸酸化至pH3,过滤,所得固体真空干燥,经硅胶柱色谱[洗脱剂:30%氨水/甲醇(体积比1:10)]纯化,得纯品N-{4-[2-(2-氨基-4,7-二氢-4-氧-1H-吡咯并[2,3-d] 嘧啶-5-基)乙基]苯甲酰基}-L-谷氨酸(哌美曲塞)0.16g, 收率75.5%, mp>260 ºC.(文献[12]报道mp>250 ºC)

137281-23-3 preparation

海关编码 2933990090
中文概述 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%